Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Schott Pharma AG KGaASHTPY -42.88%69 EV-to-OCF is 12.00 as of Aug. 17, 2026, which is 37% below its 10-year median of 19.19. GuruFocus rates SHTPY with a GF Score™ of 69/100 and a GF Value™ of $5.35. The stock has 4 warning signs investors should review. Among 851 Medical Devices & Instruments companies, Schott Pharma AG KGaA ranks worse than 70.39% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Schott Pharma AG KGaA's Enterprise Value is $2,685 Mil.
Schott Pharma AG KGaA's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $224 Mil. Therefore, Schott Pharma AG KGaA's EV-to-OCF for today is 12.00.
The historical rank and industry rank for Schott Pharma AG KGaA's EV-to-OCF or its related term are showing as below:
SHTPY'
s EV-to-OCF Range Over the Past 10 Years
Min: 9.84 Med: 19.19 Max: 33.78
Current: 17.44
During the past 6 years, the highest EV-to-OCF of Schott Pharma AG KGaA was 33.78. The lowest was 9.84. And the median was 19.19.
SHTPY's EV-to-OCF is ranked worse than 70.39% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 7.82
vs SHTPY: 17.44
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Schott Pharma AG KGaA (OTCPK:SHTPY) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Schott Pharma AG KGaA's PE Ratio (TTM) for today is calculated as:
Schott Pharma AG KGaA's share price for today is $4.37.
Schott Pharma AG KGaA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.265.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Schott Pharma AG KGaA EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Schott Pharma AG KGaA's EV-to-OCF falls into.
Schott Pharma AG KGaA's current Enterprise Value is $2,685 Mil.
Schott Pharma AG KGaA's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $224 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Schott Pharma AG KGaA (SHTPY) has a EV-to-OCF of 12.00 as of Aug. 17, 2026. This is 37% below median its historical median of 19.19. Over the past decade, Schott Pharma AG KGaA's EV-to-OCF has ranged from 9.84 to 33.78. According to the industry distribution chart, Schott Pharma AG KGaA ranks #599 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 70.4%.
Is Schott Pharma AG KGaA's EV-to-OCF too high?
Schott Pharma AG KGaA's current EV-to-OCF of 12.00 is 37% below median its 10-year median of 19.19. Over the past 10 years, this metric has ranged from a low of 9.84 to a high of 33.78. The Medical Devices & Instruments industry median EV-to-OCF is 7.82. Schott Pharma AG KGaA's value of 12.00 is 53.5% above this industry median. Based on the distribution chart, Schott Pharma AG KGaA ranks #599 out of 851 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Schott Pharma AG KGaA has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's EV-to-OCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Schott Pharma AG KGaA ranks #599 out of 851 companies for EV-to-OCF. This places Schott Pharma AG KGaA in the lower half of its industry. The industry median EV-to-OCF is 7.82. Schott Pharma AG KGaA's value of 12.00 is 53.5% above this benchmark. Historically, Schott Pharma AG KGaA's own EV-to-OCF has ranged from 9.84 to 33.78 over the past decade. While the company's 10-year median is 19.19 vs. the industry median of 7.82, Schott Pharma AG KGaA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.82, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Schott Pharma AG KGaA's current EV-to-OCF of 12.00 is 53.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Schott Pharma AG KGaA's current EV-to-OCF is 12.00, which is 37% below median its own 10-year median of 19.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Schott Pharma AG KGaA (SHTPY) has a current EV-to-OCF of 12.00. The stock's GF Value™ is $5.35, compared to a current price of $4.37 — trading 18.3% below its estimated fair value. The current EV-to-OCF is 12.00, which is 37% below median its 10-year median of 19.19 and 53.5% above the Medical Devices & Instruments industry median of 7.82. Schott Pharma AG KGaA's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Schott Pharma AG KGaA (SHTPY), the current EV-to-OCF is 12.00 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Schott Pharma AG KGaA (SHTPY) Overvalued in 2026?
Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued.
The current stock price of $4.37 is trading 18.3% below its estimated GF Value™ of $5.35.
Key valuation signals for SHTPY:
EV-to-OCF: 12.00 (37% below median its 10-year median of 19.19)
GF Value™: $5.35 vs. price of $4.37 (18.3% below fair value)
Industry Position: 53.5% above the Medical Devices & Instruments median (#599 of 851)
No single metric tells the full story. See the SHTPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
69GF Score
Get the complete analysis for SHTPY
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTPY has been successfully added to your 
